The risk of IBD in patients with IMIDs treated with targeted IL-17 inhibition has so far been investigated only for specific treatments or specific IMIDs [17–19], whereas analyses combining several drugs across multiple IMIDs are lacking. The gene discussed is IL17A; the disease is inflammatory bowel disease.